AXGN:NSD-AxoGen Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 9.59

Change

+0.19 (+2.02)%

Market Cap

USD 0.39B

Volume

0.23M

Avg Analyst Target

USD 13.50 (+40.77%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AxoGen Inc (AXGN) Stock Analysis:
Based on the AxoGen Inc stock forecasts from 1 analysts, the average analyst target price for AxoGen Inc is USD 13.50 over the next 12 months. AxoGen Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of AxoGen Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, AxoGen Inc’s stock price was USD 9.59. AxoGen Inc’s stock price has changed by +2.90% over the past week, +32.28% over the past month and -55.33% over the last year.

About

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging sever ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-10.14 (-3.03%)

USD32.85B 171.14 77.12
ALGN Align Technology Inc

-1.32 (-0.48%)

USD21.71B 31.02 18.18
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
PODD Insulet Corporation

-2.15 (-1.08%)

USD13.80B 829.42 84.91
ABMD Abiomed Inc

-0.37 (-0.15%)

USD11.58B 85.29 42.14
BRKR Bruker Corporation

-0.66 (-1.10%)

USD8.99B 33.27 17.75
SWAV ShockWave Medical Inc

+1.24 (+0.76%)

USD5.81B N/A 138.45
IART Integra LifeSciences Holdings ..

+0.39 (+0.66%)

USD4.93B 32.22 16.98
TNDM Tandem Diabetes Care Inc

-1.89 (-2.56%)

USD4.72B 307.71 186.72
IRTC iRhythm Technologies Inc

-6.04 (-4.34%)

USD3.93B N/A N/A

ETFs Containing AXGN

Symbol Name Weight Mer Price(Change) Market Cap
XMLH:XETRA Legal & General Ucits Etf.. 0.00 % 0.49 %

-0.08 (-0.67%)

USD0.13B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.35% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.35% 90% A- 90% A-
Trailing 12 Months  
Capital Gain -54.51% 43% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.51% 43% F 29% F
Trailing 5 Years  
Capital Gain -31.74% 51% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.74% 51% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 8.64% 35% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.64% 35% F 57% F
Risk Return Profile  
Volatility (Standard Deviation) 80.20% 36% F 18% F
Risk Adjusted Return 10.77% 32% F 41% F
Market Capitalization 0.39B 63% D 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.58 32% F 22% F
Price / Cash Flow Ratio -29.44 91% A- 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -22.90% 55% F 34% F
Return on Invested Capital -14.32% 53% F 35% F
Return on Assets -7.76% 61% D- 33% F
Debt to Equity Ratio 58.30% 45% F 34% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.17 61% D- 39% F
Short Percent 3.06% 58% F 49% F
Beta 0.72 75% C 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector